Sugi Predict

Sugi Predict / Compounds / SCHEMBL503944

SCHEMBL503944

SCHEMBL503944

O=C(O)CC(c1ccc(Cl)cc1)(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 1.00
▸ TSHR P16473 2/20 0.43
▸ KIF11 P52732 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ LMNA P02545 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ HIF1A Q16665 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ POLB P06746 1/20 0.40
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ GABBR2 O75899 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11615834 0.94 MIF (0.89) MIFKIF11LMNAMAPTL3MBTL1
SCHEMBL11076816 0.85 MIF (0.74) MIFTSHRALOX15LMNAKDM4E
SCHEMBL4457822 0.81 MIF (0.68) MIFTSHRKIF11LMNAKDM4E
SCHEMBL11618600 0.80 MIF (0.67) MIFKIF11LMNAMAPTL3MBTL1
SCHEMBL503257 0.79 MIF (0.65) MIFTSHRKIF11ALDH1A1MAPT
SCHEMBL24020497 0.79 MIF (0.66) MIFTSHRALOX15MAPTHIF1A
SCHEMBL8476286 0.79 CYP2C19 (0.68) MIFTSHRALOX15LMNAKDM4E
SCHEMBL2218565 0.79 MIF (0.66) MIFTSHRKIF11ALOX15LMNA
SCHEMBL987076 0.79 MIF (0.66) MIFTSHRALOX15LMNAKDM4E
SCHEMBL3025831 0.79 MIF (0.65) MIFTSHRALOX15LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
US-9505873-B2 Photopolymer formulations having a low crosslinking density COVESTRO DEUTSCHLAND AG (DE) 2016-11-29 — — US disclosed
CN-101713923-B Photopolymer formulation having a low crosslinking density BAYER MATERIALSCIENCE AG 2014-05-07 — — CN disclosed
US-8435718-B2 Upper layer-forming composition and photoresist patterning method JSR CORPORATION (JP) 2013-05-07 — — US disclosed
EP-1950610-B1 IMMERSION LITHOGRAPHIC COMPOSITION FOR FORMING UPPER FILM AND METHOD FOR FORMING PHOTORESIST PATTERN JSR CORP (JP) 2012-05-02 — — EP disclosed
US-20120028198-A1 UPPER LAYER-FORMING COMPOSITION AND PHOTORESIST PATTERNING METHOD JSR CORPORATION (JP) 2012-02-02 — — US disclosed
EP-2172504-B1 Photopolymer formulations with low interlacing density BAYER MATERIALSCIENCE AG (DE) 2011-07-20 — — EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
EP-1032385-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELLPROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2000-09-06 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
WO-1999026624-A1 USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHE AND SCOURS CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-06-03 — — WO disclosed
US-5874436-A EFFECTIVE IN INHIBITING THE ACTION OF A BACTERIAL HISTIDINE PROTEIN KINASE; USEFUL AGAINST ANTIBIOTIC RESISTANT ORGANISMS DEMERS JAMES P (US) 1999-02-23 — — US disclosed
US-5643950-A INHIBITORS OF A BACTERIAL HISTIDINE PROTEIN KINASE ORTHO PHARMACEUTICAL CORPORATION (US) 1997-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 MIF 1734/4885TSHR 2894/4885KIF11 2797/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 MIF 1696/4885TSHR 4082/4885KIF11 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.